Wells Fargo
FHTX icon

Wells Fargo’s Foghorn Therapeutics FHTX Stock Holding History

Wells Fargo’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Buy
35,301
+20,560
+139% +$91.2K ﹤0.01% 5283
2026
Q1 		$70.5K Sell
14,741
-24,014
-62% -$132K ﹤0.01% 5299
2025
Q4 		$209K Buy
38,755
+14,281
+58% +$64.7K ﹤0.01% 5040
2025
Q3 		$120K Buy
24,474
+3,431
+16% +$18.2K ﹤0.01% 5225
2025
Q2 		$98.9K Buy
21,043
+4,907
+30% +$20.5K ﹤0.01% 5199
2025
Q1 		$58.9K Buy
16,136
+295
+2% +$1.34K ﹤0.01% 5343
2024
Q4 		$74.8K Buy
15,841
+3,958
+33% +$28.8K ﹤0.01% 5345
2024
Q3 		$111K Buy
11,883
+2,611
+28% +$18.9K ﹤0.01% 4958
2024
Q2 		$53.3K Buy
9,272
+3,193
+53% +$19K ﹤0.01% 5270
2024
Q1 		$40.8K Buy
6,079
+813
+15% +$4.51K ﹤0.01% 5338
2023
Q4 		$34K Buy
5,266
+1,200
+30% +$5.18K ﹤0.01% 5418
2023
Q3 		$20.3K Sell
4,066
-4,416
-52% -$34K ﹤0.01% 5594
2023
Q2 		$59.7K Sell
8,482
-790
-9% -$5.52K ﹤0.01% 5345
2023
Q1 		$57.5K Buy
9,272
+3,883
+72% +$25.4K ﹤0.01% 5089
2022
Q4 		$34.4K Buy
5,389
+5,022
+1,368% +$37.9K ﹤0.01% 5028
2022
Q3 		$3K Sell
367
-195
-35% -$2.51K ﹤0.01% 6049
2022
Q2 		$8K Sell
562
-3,544
-86% -$45.7K ﹤0.01% 5838
2022
Q1 		$63K Sell
4,106
-6,808
-62% -$93.4K ﹤0.01% 5542
2021
Q4 		$250K Buy
+10,914
New +$157K ﹤0.01% 5138
2021
Q3 		– Sell
-38
Closed – – 7114
2021
Q2 		$0 Sell
38
-2,213
-98% -$24.1K ﹤0.01% 7037
2021
Q1 		$30K Sell
2,251
-1,496
-40% -$24.5K ﹤0.01% 6033
2020
Q4 		$76K Buy
+3,747
New +$71.8K ﹤0.01% 5453

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Wells Fargo's FHTX Position: Q2 2026 in Review

Wells Fargo increased its Foghorn Therapeutics (FHTX) stake by 139% in Q2 2026, buying an estimated $91.2K and bringing the position to 35,301 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #5283.

Wells Fargo first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $250K in Q4 2021. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Wells Fargo held 35,301 shares of Foghorn Therapeutics worth $172K as of Q2 2026.
  • Wells Fargo bought 20,560 Foghorn Therapeutics shares in Q2 2026, an estimated $91.2K.
  • Foghorn Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5283 holding.
  • Wells Fargo first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Wells Fargo's Foghorn Therapeutics position peaked at $250K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.